Literature DB >> 8855185

Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation.

L D DeLeve1.   

Abstract

Hepatic venoocclusive disease (HVOD) is caused by the disruption of the microcirculation by an as-yet unknown mechanism. Previous in vitro studies with azathioprine, monocrotaline, and dacarbazine suggested that toxins that cause HVOD initially causing HVOD target sinusoidal endothelial cells (SEC) perhaps via profound glutathione (GSH) depletion. The current study examines cyclophosphamide toxicity in SEC and hepatocytes, as well as the interplay between the two cell types. Cyclophosphamide was not directly toxic to SEC, but in coculture of SEC and hepatocytes, cyclophosphamide was significantly more toxic to SEC. Two cyclophosphamide metabolites, 4-hydroperoxycyclophosphamide and acrolein, were equally toxic to SEC, and toxicity occurred at 20-fold-lower concentrations than in hepatocytes. 4-Hydroperoxycyclophosphamide depleted GSH by greater than 95% before inducing cell death in SEC. When hepatocyte-GSH levels were sustained with supplemental methionine and serine in coculture, toxicity in both cell types was diminished. In coculture, SEC are significantly more susceptible than hepatocytes to cyclophosphamide toxicity, and this is likely caused by acrolein generated by the hepatocyte. As seen with other toxins implicated in HVOD, the profound depletion of SEC GSH precedes the onset of toxicity. The degree of cyclophosphamide toxicity induced in SEC is determined by both metabolic activation and GSH detoxification in the hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855185     DOI: 10.1002/hep.510240414

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

Review 1.  Hepatic radiation toxicity: avoidance and amelioration.

Authors:  Chandan Guha; Brian D Kavanagh
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

2.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

3.  Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.

Authors:  J S McCune; A Batchelder; K A Guthrie; R Witherspoon; F R Appelbaum; B Phillips; P Vicini; D H Salinger; G B McDonald
Journal:  Clin Pharmacol Ther       Date:  2009-03-18       Impact factor: 6.875

Review 4.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

Review 5.  Liver sinusoidal endothelial cells and liver regeneration.

Authors:  Laurie D DeLeve
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

6.  Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine.

Authors:  S Ren; J T Slatterly
Journal:  AAPS PharmSci       Date:  1999

Review 7.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

8.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Authors:  Andrew R Rezvani; Jeannine S McCune; Barry E Storer; Ami Batchelder; Aiko Kida; H Joachim Deeg; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

9.  A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

Authors:  Roberto Rodriguez; Ryotaro Nakamura; Joycelynne M Palmer; Pablo Parker; Sepideh Shayani; Auyaporn Nademanee; David Snyder; Vinod Pullarkat; Neil Kogut; Joseph Rosenthal; Eileen Smith; Chatchada Karanes; Margaret O'Donnell; Amrita Y Krishnan; David Senitzer; Stephen J Forman
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

10.  Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.

Authors:  Antonia Follenzi; Daniel Benten; Phyllis Novikoff; Louisa Faulkner; Sanj Raut; Sanjeev Gupta
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.